INSR and Alzheimer disease: Considering also that prolonged use of IRAs delivered systemically does not activate insulin receptors in normoglycemic states and thus does not promote hypoglycemia [9], many recent reviews highlight the potential of IRAs as AD therapeutics [16, 44, 58, 59].